Kian Shaker,1 Carmen Vogt,1 Yurika Katsu-Jimenéz,2 Raoul V. Kuiper,2 Kenth Andersson,1 Yuyang Li,1 Jakob C. Larsson,1 Aida Rodriguez-Garcia,2 Muhammet S. Toprakhttps://orcid.org/0000-0001-5678-5298,1 Marie Arsenian-Henriksson,2 Hans M. Hertz1
1KTH Royal Institute of Technology (Sweden) 2Karolinska Institute (Sweden)
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
X-ray fluorescence computed tomography (XFCT) with nanoparticles (NPs) as contrast agents has reached technical maturity allowing for in vivo preclinical imaging in the laboratory setting. We present the first in vivo longitudinal study with XFCT where mice were 5 times each during an 8-week period. Imaging is performed with low radiation dose (<25 mGy) and high signal-to-background for high-spatial-resolution imaging (200-400 µm) of molybdenum NP accumulations (down to ~50 µg/ml Mo). We further discuss our ongoing development of protein-coated NPs for actively targeting molecular markers (e.g., cancer), as well as potential clinical applications.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Kian Shaker, Carmen Vogt, Yurika Katsu-Jimenéz, Raoul V. Kuiper, Kenth Andersson, Yuyang Li, Jakob C. Larsson, Aida Rodriguez-Garcia, Muhammet S. Toprak, Marie Arsenian-Henriksson, Hans M. Hertz, "Preclinical in vivo x-ray fluorescence computed tomography," Proc. SPIE 11595, Medical Imaging 2021: Physics of Medical Imaging, 115951O (15 February 2021); https://doi.org/10.1117/12.2580858